Galimi Francesco
Known title: SVP & Chief Medical OfficerCIK: 0001823996
Associated companies
Transaction History
| ACET | ▼ Sell | Tax Withholding | 4,957 | $12K | 1/24/2024 | View on chart |
| ACET | ▲ Buy | Grant | 26,300 | $0 | 1/24/2024 | View on chart |
| ACET | ▼ Sell | Tax Withholding | 8,093 | $11K | 10/2/2023 | View on chart |
| ACET | ▲ Buy | Grant | 26,100 | $0 | 1/24/2023 | View on chart |
| ACET | ▼ Sell | Tax Withholding | 7,933 | $113K | 10/4/2022 | View on chart |
| ACET | ▲ Buy | Grant | 16,000 | $0 | 8/4/2022 | View on chart |
| ACET | ▼ Sell | Tax Withholding | 5,533 | $101K | 8/4/2022 | View on chart |
| ACET | ▲ Buy | Option Exercise | 6,036 | $80K | 4/4/2022 | View on chart |
| ACET | ▼ Sell | Open Market | 6,036 | $127K | 4/4/2022 | View on chart |
| ACET | ▲ Buy | Option Exercise | 168 | $1K | 4/4/2022 | View on chart |
| ACET | ▼ Sell | Open Market | 168 | $4K | 4/4/2022 | View on chart |
| ACET | ▲ Buy | Option Exercise | 1,775 | $30K | 4/4/2022 | View on chart |
| ACET | ▼ Sell | Open Market | 1,775 | $37K | 4/4/2022 | View on chart |
| ACET | ▲ Buy | Option Exercise | 7,621 | $45K | 4/1/2022 | View on chart |
| ACET | ▼ Sell | Open Market | 7,621 | $160K | 4/1/2022 | View on chart |
| ACET | ▲ Buy | Grant | 16,000 | $0 | 2/14/2022 | View on chart |
| ACET | ▼ Sell | Tax Withholding | 5,533 | $79K | 2/14/2022 | View on chart |
| ACET | ▲ Buy | Grant | 16,000 | $0 | 1/28/2022 | View on chart |
| ACET | ▼ Sell | Tax Withholding | 5,533 | $65K | 1/28/2022 | View on chart |
| ACET | ▲ Buy | Grant | 80,000 | $0 | 10/1/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
Adicet Bio shares positive Phase 1 lupus data, Wedbush lifts target
Adicet Bio announced that its Phase 1 study of Prula‑cel in lupus patients showed positive safety and efficacy signals, and the company is moving forward with plans for a pivotal trial. Wedbush analysts kept an Outperform rating and raised their price target to $28, reflecting confidence in the data. The news comes as the stock trades near its 52‑week high, with analyst consensus targets averaging $34.83.
Adicet Bio shares positive Phase 1 lupus data, Wedbush lifts target. Adicet Bio announced that its Phase 1 study of Prula‑cel in lupus patients showed positive safety and efficacy signals, and the company is moving forward with plans for a pivotal trial. Wedbush analysts kept an Outperform rating and raised their price target to $28, reflecting confidence in the data. The news comes as the stock trades near its 52‑week high, with analyst consensus targets averaging $34.83.